CA2604581A1 - Combinations, methods and compositions for treating cancer - Google Patents

Combinations, methods and compositions for treating cancer Download PDF

Info

Publication number
CA2604581A1
CA2604581A1 CA002604581A CA2604581A CA2604581A1 CA 2604581 A1 CA2604581 A1 CA 2604581A1 CA 002604581 A CA002604581 A CA 002604581A CA 2604581 A CA2604581 A CA 2604581A CA 2604581 A1 CA2604581 A1 CA 2604581A1
Authority
CA
Canada
Prior art keywords
compound
formula
pharmaceutically acceptable
combination
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002604581A
Other languages
English (en)
French (fr)
Inventor
Francis Y. Lee
Roberto Weinmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2604581A1 publication Critical patent/CA2604581A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA002604581A 2005-04-13 2006-04-13 Combinations, methods and compositions for treating cancer Abandoned CA2604581A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US67074405P 2005-04-13 2005-04-13
US60/670,744 2005-04-13
US74843305P 2005-12-08 2005-12-08
US60/748,433 2005-12-08
US11/402,502 2006-04-12
US11/402,502 US20060235006A1 (en) 2005-04-13 2006-04-12 Combinations, methods and compositions for treating cancer
PCT/US2006/013773 WO2006113304A2 (en) 2005-04-13 2006-04-13 Combinations, methods and compositions for treating cancer

Publications (1)

Publication Number Publication Date
CA2604581A1 true CA2604581A1 (en) 2006-10-26

Family

ID=37109315

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002604581A Abandoned CA2604581A1 (en) 2005-04-13 2006-04-13 Combinations, methods and compositions for treating cancer

Country Status (12)

Country Link
US (2) US20060235006A1 (US20070167479A1-20070719-C00034.png)
EP (1) EP1868435A4 (US20070167479A1-20070719-C00034.png)
JP (1) JP2008536853A (US20070167479A1-20070719-C00034.png)
KR (1) KR20080004495A (US20070167479A1-20070719-C00034.png)
AU (1) AU2006236812A1 (US20070167479A1-20070719-C00034.png)
BR (1) BRPI0608176A2 (US20070167479A1-20070719-C00034.png)
CA (1) CA2604581A1 (US20070167479A1-20070719-C00034.png)
EA (1) EA200702238A1 (US20070167479A1-20070719-C00034.png)
MX (1) MX2007012537A (US20070167479A1-20070719-C00034.png)
NO (1) NO20075087L (US20070167479A1-20070719-C00034.png)
TW (1) TW200722091A (US20070167479A1-20070719-C00034.png)
WO (1) WO2006113304A2 (US20070167479A1-20070719-C00034.png)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA01010292A (es) 1999-04-15 2002-10-23 Squibb Bristol Myers Co Inhibidores ciclicos de la proteina tirosina cinasa.
CN102886045A (zh) 2005-02-03 2013-01-23 综合医院公司 治疗吉非替尼耐药性癌症的方法
DE602006021312D1 (de) * 2005-06-09 2011-05-26 Bristol Myers Squibb Co Pharmazeutische zusammensetzung zur anwendung in der behandlung von personen mit mutant-kit-protein
AR057854A1 (es) 2005-11-04 2007-12-19 Wyeth Corp Combinaciones antineoplasicas con inhibidor de mtor, herceptina y/o hki-272 (e)-n-{4-[3-cloro-4-(2-piridinilmetoxi) anilino]-3-ciano-7-etoxi-6-quinolinil}-4-(dimetilamino)-2-butenamida
US20090099197A1 (en) * 2005-11-15 2009-04-16 Bristol-Myers Squibb Company Methods of Identifying and Treating Individuals Exhibiting MDR-1 Overexpression With Protein Tyrosine Kinase Inhibitors and Combinations Thereof
KR20140020367A (ko) * 2006-04-05 2014-02-18 노파르티스 아게 암을 치료하기 위한 ｂｃｒ-ａｂｌ/ｃ-ｋｉｔ/ｐｄｇｆ-ｒ ｔｋ 억제제를 포함하는 조합물
EP2010182A2 (en) * 2006-04-07 2009-01-07 Novartis AG Use of c-src inhibitors in combination with a pyrimidylaminobenzamide compound for the treatment of leukemia
WO2008064004A2 (en) * 2006-11-16 2008-05-29 Wyeth 4-anilino-3-quinolinecarbonitriles for the treatment of acute myelogenous leukemia (aml)
US20080119463A1 (en) * 2006-11-16 2008-05-22 Wyeth 4-Anilino-3-quinolinecarbonitriles for the treatment of acute myelogenous leukemia (AML)
WO2008089135A2 (en) * 2007-01-12 2008-07-24 University Of South Florida Identification of biomarkers predictive of dasatinib effects in cancer cells
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
WO2009076373A1 (en) * 2007-12-10 2009-06-18 Concert Pharmaceuticals Inc. Heterocyclic kinase inhibitors
EP2915532B1 (en) 2008-06-17 2016-10-19 Wyeth LLC Antineoplastic combinations containing hki-272 and vinorelbine
US8119129B2 (en) 2008-08-01 2012-02-21 Bristol-Myers Squibb Company Combination of anti-CTLA4 antibody with dasatinib for the treatment of proliferative diseases
JP5681108B2 (ja) * 2008-08-04 2015-03-04 ワイス・エルエルシー ４−アニリノ−３−シアノキノリンとカペシタビンの抗新生物薬の組合せ
US20100233172A1 (en) * 2008-12-16 2010-09-16 Bristol-Myers Squibb Company Methods of inhibiting quiescent tumor proliferation
HUE033312T2 (en) * 2009-07-20 2017-11-28 Bristol Myers Squibb Co Combination of anti CTLA4 antibody with etoposide for synergistic treatment of proliferative diseases
JP2013505968A (ja) * 2009-10-01 2013-02-21 シーエスエル、リミテッド フィラデルフィア染色体陽性白血病の治療方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6011029A (en) * 1996-02-26 2000-01-04 Bristol-Myers Squibb Company Inhibitors of farnesyl protein transferase
US7125875B2 (en) * 1999-04-15 2006-10-24 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
MXPA01010292A (es) * 1999-04-15 2002-10-23 Squibb Bristol Myers Co Inhibidores ciclicos de la proteina tirosina cinasa.
TWI310684B (en) * 2000-03-27 2009-06-11 Bristol Myers Squibb Co Synergistic pharmaceutical kits for treating cancer
EP2253319A1 (en) * 2001-05-16 2010-11-24 Novartis AG Combination comprising N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2pyrimidine-amine and a chemotherapeutic agent.
EP1534862A4 (en) * 2002-08-07 2007-10-10 Exelixis Inc RABGGT MODULATORS AND METHODS OF USE THEREOF
US20050009891A1 (en) * 2003-07-09 2005-01-13 Lee Francis Y. Combination of SRC Kinase inhibitors and chemotherapeutic agents for the treatment of proliferative diseases
AR047530A1 (es) * 2004-02-04 2006-01-25 Novartis Ag Formas de sal de 4-(4-metilpiperazin-1-ilmetil)-n-(4-metil-3-(4-piridin-3-il)pirimidin-2-ilamino)fenil)-benzamida
US7491725B2 (en) * 2004-02-06 2009-02-17 Bristol-Myers Squibb Company Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors
TW200628156A (en) * 2004-11-04 2006-08-16 Bristol Myers Squibb Co Combination of a SRC kinase inhibitor and a BCR-ABL inhibitor for the treatment of proliferative diseases

Also Published As

Publication number Publication date
NO20075087L (no) 2008-01-09
JP2008536853A (ja) 2008-09-11
EP1868435A4 (en) 2009-04-01
US20060235006A1 (en) 2006-10-19
EA200702238A1 (ru) 2008-04-28
BRPI0608176A2 (pt) 2009-11-17
AU2006236812A1 (en) 2006-10-26
US20090054415A1 (en) 2009-02-26
KR20080004495A (ko) 2008-01-09
TW200722091A (en) 2007-06-16
EP1868435A2 (en) 2007-12-26
WO2006113304A3 (en) 2007-08-02
WO2006113304A2 (en) 2006-10-26
MX2007012537A (es) 2007-12-10

Similar Documents

Publication Publication Date Title
US20090054415A1 (en) Combinations, methods and compositions for treating cancer
TWI310684B (en) Synergistic pharmaceutical kits for treating cancer
US10047078B2 (en) Aminothiazole compounds
KR101618037B1 (ko) 항종양 활성이 있는 Ａｋｔ/ＰＫＢ 저해제
RU2726367C2 (ru) Фармацевтические комбинации для лечения злокачественной опухоли
SK11082003A3 (sk) Kombinácia analógov epotilónu a chemoterapeutických činidiel na liečenie proliferatívnych ochorení
CN101222850B (zh) 治疗对药物有抗性的癌症的方法
KR20120115237A (ko) 암 치료 방법 및 조성물
JP6885629B2 (ja) インドリノン化合物の使用
JP2016539156A (ja) オーロラキナーゼ阻害剤と抗ｃｄ３０抗体の併用
JP2017530983A (ja) 相乗的オーリスタチン組合せ
Santos et al. New drugs for chronic myelogenous leukemia
Fei et al. Treatment of human pre-B acute lymphoblastic leukemia with the Aurora kinase inhibitor PHA-739358 (Danusertib)
US20100063109A1 (en) Thiadiazolidinone derivatives
WO2020132259A1 (en) Compositions and methods of treating cancers by administering a phenothiazine-related drug that activates protein phosphatase 2a (pp2a)
JP2017537974A (ja) 併用療法
BR112021007283A2 (pt) método de tratamento de um câncer ou câncer refratário
MXPA06000191A (es) Combinacion de los inhibidores de src cinasa y agentes quimioterapeuticos para el tratamiento de enfermedades proliferativas.
JP2004533992A (ja) フレデリカマイシンＡ化合物を用いたＰｉｎ１関連状態の阻害方法
Cheson New agents in follicular lymphoma
JP2006504721A (ja) 治療剤に対する乳癌耐性タンパク質（ｂｃｒｐ）−介在耐性を阻害するためのイマチニブ（グリベック、ｓｔｉ−５７１）の使用
JP2010513287A (ja) 癌治療のための組成物及び方法
KR100776184B1 (ko) 치환된 아크릴로일 디스타마이신 유도체를 포함하는, 고수준의 글루타티온과 관련된 종양 치료용 약제학적 조성물
JP6445082B2 (ja) ５’−ヒドロキシ−５−ニトロ−インジルビン−３’−オキシムを有効成分として含有する乳がん治療剤
JP2008511572A (ja) 消化管間質腫瘍を処置するためのミドスタウリンの使用

Legal Events

Date Code Title Description
FZDE Discontinued